Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Account Payables: 2012-2025

Historic Change in Account Payables for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.8 million.

  • Agios Pharmaceuticals' Change in Account Payables fell 74.51% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 44.18%. This contributed to the annual value of $6.6 million for FY2024, which is 175.59% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Change in Account Payables stood at $1.8 million for Q3 2025, which was down 53.73% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Account Payables registered a high of $8.1 million during Q4 2022, and its lowest value of -$9.8 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Account Payables was $1.4 million (2024), whereas its average is $69,000.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Change in Account Payables soared by 550.20% in 2021, and later plummeted by 297.27% in 2025.
  • Agios Pharmaceuticals' Change in Account Payables (Quarterly) stood at $5.2 million in 2021, then skyrocketed by 55.08% to $8.1 million in 2022, then plummeted by 143.80% to -$3.5 million in 2023, then soared by 78.60% to -$756,000 in 2024, then slumped by 74.51% to $1.8 million in 2025.
  • Its Change in Account Payables was $1.8 million in Q3 2025, compared to $3.9 million in Q2 2025 and -$2.8 million in Q1 2025.